<p>雅培（Abbott Laboratories，ABT）開盤下跌 4.34%。醫療服務與設備行業下跌 3.44%。該公司表現不及行業。該行業成交額前 3 的股票：Hims &amp; Hers Health Inc（HIMS）上漲 5.60%；雅培（ABT）下跌 4.34%；Danaher Corp（DHR）下跌 1.20%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png"/></p>
<h2>今天是什麼原因導致雅培（ABT）股價下跌？</h2>
<p>雅培的股票今天承受了下行壓力，主要是由於修訂後的全年收益展望。公司下調了 2026 年的調整後攤薄每股收益指引，表明其最近收購癌症診斷公司精密科學（Exact Sciences）對業績的影響。雖然這項收購旨在增強雅培在腫瘤診斷領域的市場地位，但預計會導致短期內的收益稀釋。</p>
<p>公司還報告了 2026 年第一季度的財務結果，呈現出混合的局面。該季度的收入超過了分析師的預期。然而，調整後的攤薄每股收益符合共識預期，但略微低於一些預測。此外，某些部門，如營養部門，繼續表現不佳，而快速和分子診斷部門由於呼吸病毒季節比去年輕微減弱而銷售下降。</p>
<p>投資者的謹慎情緒還受到持續的法律和運營風險的影響。最近的陪審團裁決已命令雅培在訴訟中支付鉅額賠償，指控其嬰兒配方奶粉導致壞死性小腸結腸炎。隨着許多類似訴訟的待決，這種情況引發了對潛在未來財務責任的擔憂，並影響了公司品牌形象，特別是在其營養部門。</p>
<p>分析師們也對這些發展做出了反應，一些公司下調了他們的目標價，儘管該股票的整體共識評級仍然大體積極，但這增加了投資者的謹慎情緒。</p>
<h2>雅培（ABT）的技術分析</h2>
<p>從技術上看，雅培（ABT）的 MACD（12,26,9）值為 [-2.41]，表明中性信號。RSI 為 37.33，表明中性狀態，Williams %R 為-63.78，表明超賣狀態。請密切關注。</p>
<h2>雅培（ABT）的基本面分析</h2>
<p>雅培（ABT）屬於醫療服務與設備行業。其最新年收入為 443.3 億美元，在行業中排名第三。淨利潤為 65.2 億美元，在行業中排名第二。公司簡介</p>
<p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png"/></p>
<p>在過去一個月中，多位分析師對該公司給予了買入評級，平均目標價為 132.05 美元，最高價為 158.00 美元，最低價為 113.00 美元。</p>
<h2>關於雅培（ABT）的更多細節</h2>
<p>公司特定風險：</p>
<ul>
<li>芝加哥陪審團最近裁定雅培在嬰兒配方奶粉訴訟中賠償總計 7000 萬美元，包括 1700 萬美元的懲罰性賠償，指控其產品導致早產兒壞死性小腸結腸炎（NEC），全國範圍內有超過 1700 個類似案件待決。</li>
<li>與嬰兒配方奶粉相關的高調法律裁決可能會嚴重損害雅培的品牌聲譽，特別是在其營養部門，可能導致消費者信心和市場份額下降。</li>
<li>雅培報告稱 2026 年第一季度的 GAAP 淨收益和攤薄每股收益大幅下降近 19%，主要歸因於更高的運營成本和與其最近收購相關的費用。</li>
<li>公司的 2026 年全年調整後攤薄每股收益指引包括預計來自精密科學收購的 0.20 美元稀釋，表明整合工作對財務的直接拖累。</li>
</ul>
<p>瞭解更多</p>

精密科學

雅培

基因改革 ETF - ARK

<p>雅培（Abbott Laboratories，股票代碼：ABT）開盤下跌 4.34%，醫療服務與設備行業整體下滑 3.44%。此次下跌歸因於修訂後的盈利展望，因收購精密科學（Exact Sciences）預計將稀釋收益，從而下調了 2026 年的每股收益（EPS）指引。儘管第一季度 2026 年的業績超出收入預期，但表現參差不齊，持續的法律風險以及與嬰兒配方奶粉相關的訴訟影響了品牌形象。分析師們下調了目標價，導致投資者情緒謹慎，儘管整體共識仍然積極</p>

<p>Abbott Laboratories (ABT) opened down by 4.34%. The Healthcare Services &amp; Equipment sector is down by 3.44%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Hims &amp; Hers Health Inc (HIMS) up 5.60%; Abbott Laboratories (ABT) down 4.34%; Danaher Corp (DHR) down 1.20%.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories，ABT）開盤下跌 4.34%。醫療服務與設備行業下跌 3.44%。該公司表現不及行業。該行業成交額前 3 的股票：Hims &amp; Hers Health Inc（HIMS）上漲 5.60%；雅培（ABT）下跌 4.34%；Danaher Corp（DHR）下跌 1.20%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png" alt="" original-src="https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png"/></p>
<h2>What is driving Abbott Laboratories (ABT)’s stock price down today?</h2>
<div class="lb-trans"><h2>今天是什麼原因導致雅培（ABT）股價下跌？</h2>
</div><p>Abbott Laboratories' stock experienced downward pressure today, primarily driven by a revised full-year earnings outlook. The company lowered its adjusted diluted earnings per share guidance for 2026, indicating an impact from its recent acquisition of cancer diagnostics firm Exact Sciences. While this acquisition is intended to strengthen Abbott's market position in oncology diagnostics, it is expected to result in a near-term earnings dilution.</p>
<div class="lb-trans"><p>雅培的股票今天承受了下行壓力，主要是由於修訂後的全年收益展望。公司下調了 2026 年的調整後攤薄每股收益指引，表明其最近收購癌症診斷公司精密科學（Exact Sciences）對業績的影響。雖然這項收購旨在增強雅培在腫瘤診斷領域的市場地位，但預計會導致短期內的收益稀釋。</p>
</div><p>The company also reported its first-quarter 2026 financial results, which presented a mixed picture. Revenue for the quarter surpassed analyst forecasts. However, adjusted diluted earnings per share met consensus estimates but slightly missed some predictions. Furthermore, certain segments, such as Nutrition, continued to show underperformance, and the Rapid and Molecular Diagnostics division experienced a decline in sales due to a less severe respiratory virus season compared to the prior year.</p>
<div class="lb-trans"><p>公司還報告了 2026 年第一季度的財務結果，呈現出混合的局面。該季度的收入超過了分析師的預期。然而，調整後的攤薄每股收益符合共識預期，但略微低於一些預測。此外，某些部門，如營養部門，繼續表現不佳，而快速和分子診斷部門由於呼吸病毒季節比去年輕微減弱而銷售下降。</p>
</div><p>Adding to investor caution are ongoing legal and operational risks. Recent jury verdicts have ordered Abbott to pay significant damages in lawsuits alleging that its infant formula caused necrotizing enterocolitis. With numerous similar lawsuits pending, this situation raises concerns about potential future financial liabilities and impacts the company's brand perception, particularly within its Nutrition segment.</p>
<div class="lb-trans"><p>投資者的謹慎情緒還受到持續的法律和運營風險的影響。最近的陪審團裁決已命令雅培在訴訟中支付鉅額賠償，指控其嬰兒配方奶粉導致壞死性小腸結腸炎。隨着許多類似訴訟的待決，這種情況引發了對潛在未來財務責任的擔憂，並影響了公司品牌形象，特別是在其營養部門。</p>
</div><p>Analysts have also reacted to these developments, with some firms adjusting their price targets downwards, contributing to a cautious sentiment among investors, despite the overall consensus rating for the stock remaining largely positive.</p>
<div class="lb-trans"><p>分析師們也對這些發展做出了反應，一些公司下調了他們的目標價，儘管該股票的整體共識評級仍然大體積極，但這增加了投資者的謹慎情緒。</p>
</div><h2>Technical Analysis of Abbott Laboratories (ABT)</h2>
<div class="lb-trans"><h2>雅培（ABT）的技術分析</h2>
</div><p>Technically, Abbott Laboratories (ABT) shows a MACD (12,26,9) value of [-2.41], indicating a neutral signal. The RSI at 37.33 suggests neutral condition and the Williams %R at -63.78 suggests oversold condition. Please monitor closely.</p>
<div class="lb-trans"><p>從技術上看，雅培（ABT）的 MACD（12,26,9）值為 [-2.41]，表明中性信號。RSI 為 37.33，表明中性狀態，Williams %R 為-63.78，表明超賣狀態。請密切關注。</p>
</div><h2>Fundamental Analysis of Abbott Laboratories (ABT)</h2>
<div class="lb-trans"><h2>雅培（ABT）的基本面分析</h2>
</div><p>Abbott Laboratories (ABT) is in the Healthcare Services &amp; Equipment industry. Its latest annual revenue is $44.33B, ranking 3 in the industry. The net profit is $6.52B, ranking 2 in the industry. Company Profile</p>
<div class="lb-trans"><p>雅培（ABT）屬於醫療服務與設備行業。其最新年收入為 443.3 億美元，在行業中排名第三。淨利潤為 65.2 億美元，在行業中排名第二。公司簡介</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png" alt="" original-src="https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png"/></p>
<p>Over the past month, multiple analysts have rated the company as Buy, with an average price target of $132.05, a high of $158.00, and a low of $113.00.</p>
<div class="lb-trans"><p>在過去一個月中，多位分析師對該公司給予了買入評級，平均目標價為 132.05 美元，最高價為 158.00 美元，最低價為 113.00 美元。</p>
</div><h2>More details about Abbott Laboratories (ABT)</h2>
<div class="lb-trans"><h2>關於雅培（ABT）的更多細節</h2>
</div><p>Company Specific Risks:</p>
<div class="lb-trans"><p>公司特定風險：</p>
</div><ul>
<li>A Chicago jury recently awarded a total of $70 million, including $17 million in punitive damages, against Abbott Laboratories in infant formula lawsuits alleging its product caused necrotizing enterocolitis (NEC) in premature infants, with over 1,700 similar cases pending nationwide.</li>
<li>The ongoing high-profile legal verdicts related to infant formula have the potential to severely damage Abbott's brand reputation, particularly within its nutrition division, possibly leading to decreased consumer confidence and market share.</li>
<li>Abbott reported a significant nearly 19% decline in GAAP net earnings and diluted EPS for Q1 2026, primarily attributed to higher operating costs and charges related to its recent acquisition.</li>
<li>The company's full-year 2026 adjusted diluted EPS guidance includes a projected $0.20 dilution from the Exact Sciences acquisition, indicating an immediate financial drag from integration efforts.</li>
</ul>
<div class="lb-trans"><ul>
<li>芝加哥陪審團最近裁定雅培在嬰兒配方奶粉訴訟中賠償總計 7000 萬美元，包括 1700 萬美元的懲罰性賠償，指控其產品導致早產兒壞死性小腸結腸炎（NEC），全國範圍內有超過 1700 個類似案件待決。</li>
<li>與嬰兒配方奶粉相關的高調法律裁決可能會嚴重損害雅培的品牌聲譽，特別是在其營養部門，可能導致消費者信心和市場份額下降。</li>
<li>雅培報告稱 2026 年第一季度的 GAAP 淨收益和攤薄每股收益大幅下降近 19%，主要歸因於更高的運營成本和與其最近收購相關的費用。</li>
<li>公司的 2026 年全年調整後攤薄每股收益指引包括預計來自精密科學收購的 0.20 美元稀釋，表明整合工作對財務的直接拖累。</li>
</ul>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div>

Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know

TradingKey

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - SPDR

基因免疫&健康關懷 ETF - iShares

醫療業 ETF - Vanguard

美國醫療保健供應商 ETF - iShares

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做空 - Direxion

美國醫藥設備 ETF - iShares

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

標普健康醫療設備 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

標普全球醫療股指數 ETF - iShares

動態生物技術與基因組 ETF - Invesco

美國制藥 ETF - iShares

Hims & Hers Health

丹納赫

雅培公司股票（ABT）在 4 月 16 日開盤下跌 4.34%：投資者需要了解的事項